首页> 外文期刊>IUBMB life >Targeting Glioblastoma Stem Cells (GSCs) with Peroxisome Proliferator-activated Receptor Gamma (PPAR gamma) Ligands
【24h】

Targeting Glioblastoma Stem Cells (GSCs) with Peroxisome Proliferator-activated Receptor Gamma (PPAR gamma) Ligands

机译:用过氧化物酶体增殖物激活的受体γ(PPARγ)配体靶向胶质母细胞瘤干细胞(GSC)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Glioblastoma multiforme (GBM), also known as glioblastoma, is the most common and aggressive brain tumor. GBM has a poor survival rate and high resistance to standard therapy, leading to recurrence and metastasis to adjacent normal regions. Glioblastoma stem cells (GSCs) are regarded as an emerging target for therapy of GBM. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that functions in a variety of cancers and in normal adipocyte differentiation. The newly discovered connection between PPAR gamma ligands and cancer stem cells (CSCs) raises important implications for the potential therapeutic use of synthetic PPAR gamma ligands, such as thiazolidinediones (TZDs), in glioblastoma. Here, I hypothesize that synthetic PPAR gamma ligands serve to modulate stemness-related molecules and several signaling pathway in GSCs and I propose potential experimental approaches to investigate the effects of these ligands on GSCs in vitro and in vivo.
机译:多形胶质母细胞瘤(GBM),也称为胶质母细胞瘤,是最常见的侵袭性脑肿瘤。 GBM的生存率低,对标准疗法的抵抗力强,导致复发和转移至邻近的正常区域。胶质母细胞瘤干细胞(GSC)被认为是GBM治疗的新兴靶标。过氧化物酶体增殖物激活受体γ(PPAR gamma)是一种核受体,在多种癌症和正常脂肪细胞分化中起作用。 PPARγ配体与癌症干细胞(CSC)之间的新发现联系对胶质母细胞瘤中合成的PPARγ配体(如噻唑烷二酮(TZD))的潜在治疗用途提出了重要的建议。在这里,我假设合成的PPARγ配体可用于调节GSC中与茎相关的分子和几种信号传导途径,并且我提出了潜在的实验方法来研究这些配体在体外和体内对GSC的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号